Omeiza Favour O, Ademowo George O, Ayeni Funmilola A
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria.
Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Malar J. 2020 Nov 19;19(1):414. doi: 10.1186/s12936-020-03486-0.
The menace of resistance to anti-malarial drugs is a great challenge to malaria control, necessitating the search for new anti-malarial agents. This search has led to the exploration of natural products for efficacy in malaria therapy. Omidun is the supernatant of fermenting maize (ogi) slurry that has been widely investigated and reported to possess several health benefits and it is used traditionally as solvent for preparing anti-malarial herbs. However, there is no information on the anti-malarial activity of omidun itself. This study was conducted to investigate the prophylactic, curative and suppressive anti-malarial potential of omidun.
Experimental mice in the curative group were infected with 1 × 10 cells of Plasmodium berghei strain ANKA and treated with either 0.2 ml of omidun containing 3 × 10 cfu/ml of viable lactic acid bacteria or 0.2 ml of 5 mg/kg of chloroquine (positive control) or 0.2 ml of saline (negative control) for 4 days from day 3 post infection. The prophylactic group of mice were pre-treated with either omidun, chloroquine or saline for 4 days before infection with P. berghei, while the suppressive group was treated with omidun or chloroquine or saline and infected with P. berghei simultaneously. A group of mice were uninfected but treated (with omidun and control samples), while a final group was uninfected and untreated (controls). Parasitaemia and histopathology analysis were done in all groups.
The curative and suppressive groups showed a significant difference between the omidun-treated mice (100% parasitaemia reduction) and the untreated mice (54.5% parasitaemia increase). There was no significance difference between the omidun treatment and chloroquine (positive control) treatment in suppressive group as both treatment had 100% parasitaemia reduction. The omidun prophylactic treatment however did not show any parasitaemia suppression, but a significant difference was observed between the omidun treatment (85% increase) and the chloroquine (positive control) treatment (100% reduction) in the group. Omidun treatment is non-toxic to the kidney.
This study provides scientific evidence supporting omidun usage in the treatment of malaria. Consequently, further work may yield the specific component of omidun responsible for the anti-malarial activity.
抗疟药物耐药性的威胁是疟疾防控面临的巨大挑战,因此有必要寻找新的抗疟药物。这促使人们探索天然产物在疟疾治疗中的功效。奥米顿是发酵玉米(奥吉)浆液的上清液,已被广泛研究并报道具有多种健康益处,传统上它被用作制备抗疟草药的溶剂。然而,关于奥米顿本身的抗疟活性尚无相关信息。本研究旨在调查奥米顿的预防、治疗和抑制疟疾的潜力。
治疗组的实验小鼠感染1×10个伯氏疟原虫ANKA株细胞,从感染后第3天起,分别用0.2毫升含有3×10cfu/ml活乳酸菌的奥米顿、0.2毫升5毫克/千克氯喹(阳性对照)或0.2毫升生理盐水(阴性对照)治疗4天。预防组的小鼠在感染伯氏疟原虫前,先用奥米顿、氯喹或生理盐水预处理4天,而抑制组则同时用奥米顿、氯喹或生理盐水治疗并感染伯氏疟原虫。一组小鼠未感染但接受治疗(用奥米顿和对照样本),最后一组未感染且未接受治疗(对照组)。对所有组进行了寄生虫血症和组织病理学分析。
治疗组和抑制组中,接受奥米顿治疗的小鼠(寄生虫血症减少100%)与未治疗的小鼠(寄生虫血症增加54.5%)之间存在显著差异。抑制组中,奥米顿治疗与氯喹(阳性对照)治疗之间无显著差异,因为两种治疗的寄生虫血症均减少100%。然而,奥米顿预防治疗未显示出任何寄生虫血症抑制作用,但该组中奥米顿治疗(增加85%)与氯喹(阳性对照)治疗(减少100%)之间观察到显著差异。奥米顿治疗对肾脏无毒。
本研究提供了支持奥米顿用于治疗疟疾的科学证据。因此,进一步的研究可能会找出奥米顿中负责抗疟活性的特定成分。